Name: Christer Nordstedt
Title: Acting CEO
Born: 1962
Share holdings: –
Education: Christer Nordstedt is a Doctor of Medicine and has a PhD in Pharmacology and Biochemistry from the Karolinska Institute in Sweden and did his postdoctoral training with the Nobel laureate Paul Greengard at Rockefeller University in New York.
Previous experience: Christer Nordstedt has many years of experience, including leading a large number of projects in the pharmaceutical industry from the earliest discovery all the way through clinical development, and has held positions such as Global Head of Specialty Research and Clinical Development and Senior Vice President Global Head of Clinical Development at Teva Pharmaceuticals, Head of R&D at Orion Cooperation as well as Senior Vice President at Hoffman-LaRoche in Basel and at Eli Lilly in Indianapolis.
Other assignments: Chairman of the Board of WntResearch AB and engaged as a consultant at BioArctic AB.
Name: Robert Maiorana
Title: Acting Chief Financial Officer
Born: 1960
Share holdings: 20,000
Education: Bachelor of Science in Business and Economics from Lund University
Previous experience: Robert Maiorana has worked for Vivesto since the second half of 2020 and as Finance Manager since March 2021. Robert has extensive finance experience from senior positions. He has previously worked as a Finance and Management Consultant at Nacka Municipality and Bactiguard Holding AB and CFO at International Copyright Enterprise Services AB, ParaCell Solutions AB and MFEX Mutual Funds Exchange AB. He was also Head of Finance at Ryds Bilglas AB and ABN AMRO Bank Sweden.
Name: Reinhard Koenig
Title: Chief Scientific Officer
Born: 1960
Share holdings: –
Education:
- Medical Doctor, Philipps University Marburg, Germany
- Doctorate in Medicine, Philipps University Marburg, Germany
Previous experience: Reinhard Koenig is a Medical Scientist, Advisor and Executive with successful track record in obtaining product approvals and driving commercialization in Europe and the United States in biotech, pharmaceuticals and medical devices. His experience of more than 25 years spans start-up and early stage companies as well as large, multi-national enterprises. He has held senior and executive positions in privately held and publicly traded companies, among them Genentech, Inc., Piramal Critical Care, Inc., Boehringer Mannheim Therapeutics, Inc., Questcor Pharmaceuticals, Inc., Collagen Aesthetics, Inc., and others.
He has published on various scientific topics and is inventor and co-inventor of several patents and pending applications and held an appointment as Adjunct Professor at Temple University’s College of Engineering, Department of Bioengineering, Philadelphia.
Name: Johanna Röstin
Title: Head of Regulatory Affairs
Born: 1967
Share holdings: –
Education: M.Sc in chemical engineering / biotechnology and a Licentiate degree in biotechnology from the KTH Royal Institute of Technology in Stockholm
Previous experience: Johanna Röstin has more than 25 years of experience within the Pharmaceutical and Biotech industry with expertise within development, project management and regulatory affairs. She was previously Director of CMC, Program Management and Regulatory at OxThera AB and before that she spent 10 years at Swedish Orphan Biovitrum AB (Sobi), where she was regulatory responsible for one of Sobi’s leading biological products commercialized in the EU and US as Global Senior Regulatory Affairs Manager. She was also Regulatory CMC expert for commercial- and development-stage biological products at SOBI. Other employers include Pharmacia and Biovitrum.
Name: Daniel Tesfa
Title: Chief Medical Officer
Born: 1969
Share holdings: –
Education: PhD in Medicine from Karolinska Institutet and an M.D. from the University of Lund, Sweden. He is also a fellow of Swedish Society of Medicine, and a member of the Swedish Hematology and Oncology Association.
Previous experience: Daniel Tesfa brings extensive experience in clinical development and precision oncology over 20 years. Most recently he served as Medical Director, Clinical and Translation Science Hematology at listed Swedish biopharmaceutical company SOBI (Swedish Orphan Biovitrum AB), where he led clinical development. From 2018 until 2020 he worked as Head of Oncology and Hematology at Bayer, Scandinavia, where he was a Medical Advisor and manager for the medical team. Other prior roles include Country Medical Manager Oncology and Hematology, at Roche, Sweden.
Name: Kai Wilkinson
Title: Chief Technical Officer
Born: 1981
Share holdings: –
Education: PhD In Inorganic chemistry from was previously University of Agricultural Sciences, MSc. In Chemical Engineering and Biotechnology from Mälardalen University.
Previous experience: Kai Wilkinson was previously Head of Research, Development and Manufacturing at Oasmia. Before joining Oasmia in 2021 he spent 8 years in different positions at Fresenius Kabi AB, including Formulation Scientist and CMC Lead, Parenteral emulsions product specialist, and Pilot Plant production process development.
